Truist Securities raised its price target for Boston Scientific (BSX) from $120 to $125 after the company reported a strong quarter with earnings beats and growth in key divisions. The firm expects continued upside potential for BSX in 2025, though it notes AI stocks may offer higher returns.

Boston Scientific Corporation (BSX) has outperformed the broader market and S&P 500 Index in 2025, driven by strong product portfolio, FDA approvals, and acquisitions. Analysts maintain a 'Strong Buy' rating, with price targets implying significant upside potential.

The article analyzes Boston Scientific's (BSX) stock performance, discussing brokerage recommendations and the reliability of Wall Street analysts' views. It highlights the company's average brokerage recommendation (ABR) of 1.16, which leans toward a 'Strong Buy,' and contrasts this with the Zacks Rank system, which assigns a 'Buy' rating based on earnings estimate revisions. The article emphasizes the limitations of brokerage recommendations and advocates for using tools like Zacks Rank for investment decisions.

Boston Scientific Corp released its Form 10-Q report for Q2 2025, highlighting strong financial performance with net sales of $5.061 billion, gross profit of $3.424 billion, and net income of $795 million. The report details revenue by segment, geographic performance, new product acquisitions, and future growth plans in Cardiology and Peripheral Interventions.

TransMedics Group (TMDX) reported strong Q2 2025 earnings, with EPS rising 162.9% YoY and revenue up 37.7% YoY. The company's stock surged 10.5% following the results, outperforming the S&P 500. Other medical sector companies like Medpace, West Pharmaceutical, and Boston Scientific also exceeded earnings estimates.